Dumitrescu Daniel, Nagel Christian, Kovacs Gabor, Bollmann Tom, Halank Michael, Winkler Jörg, Hellmich Martin, Grünig Ekkehard, Olschewski Horst, Ewert Ralf, Rosenkranz Stephan
Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin, Cologne, Germany.
Cologne Cardiovascular Research Center (CCRC), University of Cologne, Germany.
Heart. 2017 May;103(10):774-782. doi: 10.1136/heartjnl-2016-309981. Epub 2017 Jan 6.
Pulmonary arterial hypertension (PAH) is a devastating disease with limited survival and occurs as a frequent complication in patients with systemic sclerosis (SSc). A definite diagnosis of PAH is obtained by right heart catheterisation (RHC); however, the initial suspicion is raised by non-invasive methods. We assessed the diagnostic accuracy of key parameters derived from cardiopulmonary exercise testing (CPET) for detecting and ruling out SSc-associated PAH.
In a multicentre setting, we prospectively evaluated 173 consecutive patients with SSc without known PAH, but with clinical suspicion of PAH. Each patient underwent CPET and RHC.
RHC identified PAH in 48 patients (27.8%), postcapillary pulmonary hypertension (PH) in 10 patients (5.8%) and ruled out PH in 115 patients (66.5%). CPET parameters correlated significantly with pulmonary haemodynamics. PeakVO and VE/VCO showed highest correlations with pulmonary arterial pressure, transpulmonary pressure gradient and pulmonary vascular resistance. Several parameters showed high sensitivity and specificity for PAH detection by receiver operating characteristic analysis. However, peakVO showed highest diagnostic accuracy (sensitivity 87.5%, specificity 74.8% at a threshold level of 13.8 mL/min/kg). A peakVO of >18.7 mL/kg/min was reached by 38/173 patients (22%) and excluded PAH in our cohort (negative predictive value 1.0). A nadir VE/VCO ratio of >45.5 showed a positive predictive value of 1.0. Diagnostic accuracy was highest in patients with low pulmonary arterial wedge pressure (<12 mm Hg). There were no study-related serious adverse events.
CPET is a safe and valuable method in the non-invasive detection of SSc-associated PAH. It may be particularly beneficial for reducing unnecessary RHC procedures.
肺动脉高压(PAH)是一种预后不良的疾病,生存率有限,且是系统性硬化症(SSc)患者常见的并发症。PAH的确切诊断需通过右心导管检查(RHC)来确定;然而,最初的怀疑是由非侵入性方法引起的。我们评估了心肺运动试验(CPET)得出的关键参数对检测和排除SSc相关PAH的诊断准确性。
在多中心研究中,我们前瞻性评估了173例连续的无已知PAH但临床怀疑有PAH的SSc患者。每位患者均接受了CPET和RHC检查。
RHC检查发现48例患者(27.8%)患有PAH,10例患者(5.8%)患有毛细血管后肺动脉高压(PH),115例患者(66.5%)排除了PH。CPET参数与肺血流动力学显著相关。峰值摄氧量(PeakVO)和每分钟通气量与二氧化碳排出量之比(VE/VCO)与肺动脉压、跨肺压梯度和肺血管阻力的相关性最高。通过受试者工作特征分析,几个参数对PAH检测具有较高的敏感性和特异性。然而,PeakVO显示出最高的诊断准确性(在阈值水平为13.8 mL/min/kg时,敏感性为87.5%,特异性为74.8%)。173例患者中有38例(22%)达到PeakVO>18.7 mL/kg/min,在我们的队列中排除了PAH(阴性预测值为1.0)。最低VE/VCO比值>45.5时,阳性预测值为1.0。在肺动脉楔压较低(<12 mm Hg)的患者中,诊断准确性最高。没有与研究相关的严重不良事件。
CPET是无创检测SSc相关PAH的一种安全且有价值的方法。它对于减少不必要的RHC检查可能特别有益。